Crescent Biopharma (CBIO) Other Gross PP&E Adjustments (2016 - 2026)
Crescent Biopharma (CBIO) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with -$1.4 million as the latest value for Q1 2026.
- For Q1 2026, Other Gross PP&E Adjustments fell 84.39% year-over-year to -$1.4 million; the TTM value through Mar 2026 reached -$1.4 million, down 12.66%, while the annual FY2025 figure was -$1.5 million, N/A changed from the prior year.
- Other Gross PP&E Adjustments hit -$1.4 million in Q1 2026 for Crescent Biopharma, up from -$1.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $1.4 million in Q1 2023 and bottomed at -$1.6 million in Q2 2025.
- Average Other Gross PP&E Adjustments over 5 years is -$173547.8, with a median of -$608932.5 recorded in 2024.
- Year-over-year, Other Gross PP&E Adjustments surged 340.08% in 2022 and then crashed 246.39% in 2024.
- Crescent Biopharma's Other Gross PP&E Adjustments stood at $1.4 million in 2022, then plummeted by 187.58% to -$1.2 million in 2023, then skyrocketed by 60.75% to -$473770.0 in 2024, then tumbled by 210.07% to -$1.5 million in 2025, then rose by 6.6% to -$1.4 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$1.4 million, -$1.5 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.